The results revealed an increase in FMO1 and LPL expression levels and a decrease in AMDHD1 and P4HA1 expression levels among patients in the NASH group compared to the HC group in the training cohort (Fig. 6A). Here, FMO1 is linked to metabolic dysfunction-associated steatohepatitis.